INTRODUCTION: @entity2591 is a therapeutic alternative to low-dose @entity2592 in @entity1 with @entity3052 ( @entity3052 ) who are unfit for intensive chemotherapy. @entity1 AND METHODS: We retrospectively analyzed all @entity3052 @entity1 treated with @entity2591 at the University Hospital Zurich and the Kantonsspital Munsterlingen between January 2005 and December 2011. The primary end point was overall survival (OS). RESULTS: Thirty-eight @entity1 were included in the analysis. Twenty-one (55%) @entity1 had newly diagnosed @entity3052 , 14 (37%) had relapsed @entity3052 , and 3 (8%) underwent bridging therapy before allogeneic stem-cell transplantation. Age at diagnosis was 72 years in the newly diagnosed cohort and 58 years in the relapsed cohort, 19 (50%) @entity1 were female, 20 (53%) @entity1 were transfusion dependent, and bone marrow blast count was 43% (interquartile range, 26-80). Most @entity1 (58%) had poor or very poor risk @entity3052 . @entity1 received a median (range) of 7 (3-13) therapy cycles. The median (range) OS in the newly diagnosed and previously treated @entity1 groups were 308 (175-580) days and 346 (293-628) days, respectively (P  = .94). Median OS in the 3 @entity1 treated before allogeneic stem-cell transplantation has not been reached. Sixty-day mortality was 7.9%, with no difference between the 2 groups. Ongoing or increasing transfusion dependency was associated with adverse outcome (hazard ratio, 3.09; 95% confidence interval, 1.29-7.37, P  = .011). CONCLUSION: Treatment with @entity2591 led to a median OS of 10 months in both a previously untreated and a previously treated frail @entity3052 @entity1 cohort. A positive effect in transfusion dependency was observed in 29% of these @entity1 and was associated with better survival.

Efficacy of @entity2591 in De Novo and Relapsed XXXX : A Retrospective Comparative Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS'] @entity2591 :: ('MESH:D001374', 'Chemical') :: ['Azacitidine', 'azacitidine'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia', 'AML'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine']
@entity3052 :: (MESH:D015470,Disease) :: ['Acute Myeloid Leukemia']
